Conditionally replicating herpes vectors for cancer therapy

This publication has 26 references indexed in Scilit:

• Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
  Cancer Gene Therapy, 2000
• Corticosteroid Administration Does Not Affect Viral Oncolytic Activity, but Inhibits Antitumor Immunity in ReplicationCompetent Herpes Simplex Virus Tumor Therapy
  Human Gene Therapy, 1999
• Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice
  Gene Therapy, 1999
• Herpes Simplex Virus as an in Situ Cancer Vaccine for the Induction of Specific Anti-Tumor Immunity
  Human Gene Therapy, 1999
• Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1
  Human Gene Therapy, 1998
• Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector
  Gene Therapy, 1998
• Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors
  Gene Therapy, 1998
• Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
  Gene Therapy, 1998
• Toxicity and Neuronal Infection of a HSV-1 ICP34.5 Mutant in Nude Mice
  Journal of NeuroVirology, 1998
• Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir
  Neurosurgery, 1993